Therefore, treatment-refractory HR+, HER2-, advanced breast cancer patients may undergo F1CDx analysis to determine if they possess a PIK3CA mutation and therefore may benefit from alpelisib treatment. Here, ERBB2 is linked to breast carcinoma.